BPH Procedure Volume Trends in the US (2023–2025): A Stable Market with Shifting Distribution

Apr 3

2 min read

Stable volume, shifting distribution, and a persistent diagnosis–treatment gap

The US BPH procedure market remained stable from 2023 to 2025 (~280,000–300,000 procedures/year)
Approximately ~4.1% of diagnosed BPH patients underwent procedures in 2025
The majority (95.9%) were managed medically or remained untreated
TURP remains the most common (53.7%); other options are gaining share, partly driven by expanding commercial payer coverage.

Overview

The US market for benign prostatic hyperplasia (BPH) procedures has remained stable from 2023 to 2025. Across TURP, HoLEP, UroLift, Rezum, and Aquablation, total volume was 284,696 in 2023, 282,288 in 2024, and 288,935 in 2025.

Including emerging options, total 2025 volume approaches ~301,000. While overall utilization has not expanded, distribution across procedures has shifted.

Diagnosis vs. Treatment

In 2025, over 7.3 million patients in the US carried a BPH diagnosis (ICD-10 N40.0, N40.1). Approximately 4.1% underwent a procedure, while 95.9% were managed without procedural intervention.

This gap reflects current care patterns and may relate to referral pathways, access, and variation in evaluation and treatment thresholds. Claims data reflects utilization, not causality.

Payer Mix

Medicare Fee-for-Service and Medicare Advantage accounted for 80.8% of procedures in 2025, reflecting the age distribution of BPH and the influence of CMS policy.

Trends by BPH Procedure Type (2025 Snapshot)

In 2025, TURP remains the most commonly performed procedure (155,183; 53.7%). HoLEP accounts for 34,704 procedures (12.0%). UroLift accounts for 38,207 procedures and remains widely used in office-based settings. Rezum accounts for 15,806 procedures across practices. Aquablation accounts for 45,035 procedures (15.6%), primarily in hospital-based settings.

Comparing those of 2024, these data show stable total volume with shifting distribution across modalities. They describe utilization patterns and do not indicate clinical outcomes or a preferred treatment approach.

Procedure selection remains dependent on patient characteristics, anatomy, comorbidities, and clinical judgment.

Conclusion

From 2023 to 2025, the BPH procedural market remained stable in volume while evolving in distribution. Most diagnosed patients did not undergo procedural treatment, highlighting the gap between diagnosis and intervention.

What percentage of BPH patients undergo surgery? About 4.1% of diagnosed patients in the US underwent a procedure in 2025.

What is the most common BPH procedure? TURP remains the most common (53.7% share in 2025).